Medical Document Management Systems Market Expected to Reach Around $424.5 Million by 2019

 

January 05, 2015 -- The global medical document management systems market is estimated to be worth around $220 million in 2014 and grow at a CAGR of 13%-14% during the forecast period of 2014 to 2019. This report studies the medical document management systems market over the forecast period of 2014-2019.

http://www.marketsandmarkets.com/Market-Reports/medical-document-management-systems-market-191026305.html 
Early buyers will receive 10% customization on this report.

The medical document management systems market recorded a healthy growth rate during the last few years, primarily attributed to the need for digitization and automation in the healthcare sector. Rising need to comply with regulations and laws to avoid penalties and the need to improve the quality of healthcare and increase clinical efficiency. Government initiatives and funding to bring e-Health to the healthcare sector across the globe has driven the adoption of EMR systems and other healthcare IT systems. All these systems necessitate the deployment of document management systems to streamline the workflow and manage business processes. The factors such as the need to curtail healthcare delivery costs and create a paperless environment to reduce medical errors are expected to drive this market in the coming years. Other factors are the increasing number of multi-specialty hospitals, modernization in healthcare and improved clinical studies through computerized patient case notes. However, the large number of players in this market and difficulties in integration of document management systems with other existing IT systems are posing a big challenge to market growth.

For Report Inquiry at http://www.marketsandmarkets.com/Enquiry_Before_Buying.asp?id=191026305

In this report, the market is segmented by products, applications, modes of delivery, end users and region. The report also discusses the key market drivers and restraints of and the opportunities and trends in this market and its sub-markets. The market is expected to grow at a double-digit CAGR from 2014 to 2019.

In 2013, North America was the major market for medical document management systems, followed by Europe and Asia-Pacific. Highly developed healthcare IT infrastructure, number of healthcare reforms and advent of new technologies and favorable regulatory compliance in the North American and European region has led to the major contribution of these regions to the global medical document management market. However, the growth opportunities for this market are highest in the Asia-Pacific and RoW regions. The APAC market is expected to grow at a highest CAGR during the forecast period.

For PDF Manual at http://www.marketsandmarkets.com/pdfdownload.asp?id=191026305

Prominent players in the medical document management systems market include McKesson Corporation (U.S.), 3M Company (U.S.), Siemens Medical Solutions USA, Inc. (U.S.), GE Healthcare (U.S.), Allscripts Healthcare Solutions, Inc. (U.S.), Toshiba Medical systems Corporation (Japan), Cerner Corporation (U.S.), Kofax Ltd (U.S.), EPIC systems (U.S.) and Hyland Software (U.S.).

Browse Related Reports: 
Patient Flow Management Solutions Market by Type (RTLS, Event Driven), Product (Integrated, Standalone), Component (Hardware, Software, Services); Delivery Mode (Web-based, On-premise, Cloud-based) - Trends & Global Forecasts to 2019 
http://www.marketsandmarkets.com/Market-Reports/patient-flow-management-solutions-market-116094242.html

Laboratory Information Management Systems/ LIMS Market by Product (COTS & Legacy), Delivery Mode (On-premise, Hosted, Cloud), Component (Software & Services), End User Industries (Healthcare, CRO, Petrochemical, Oil and Gas, Chemical) - Forecast to 2019 
http://www.marketsandmarkets.com/Market-Reports/laboratory-information-management-systems-market-250610373.html

About MarketsandMarkets

MarketsandMarkets is world’s No. 2 firm in terms of annually published premium market research reports. Serving 1700 global fortune enterprises with more than 1200 premium studies in a year, M&M is catering to multitude of clients across 8 different industrial verticals. We specialize in consulting assignments and business research across high growth markets, cutting edge technologies and newer applications. Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors.

M&M’s flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets. The new included chapters on Methodology and Benchmarking presented with high quality analytical infographics in our reports gives complete visibility of how the numbers have been arrived and defend the accuracy of the numbers.

We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository. 
Contact: 
Mr. Rohan 
North - Dominion Plaza, 
17304, Preston Road, 
Suite 800, Dallas, TX 75252 
Tel: +1-888-600-6441 
e-mail: sales(at)marketsandmarkets(dot)com 
Visit MarketsandMarkets Blog at http://mnmblog.org/market-research/healthcare/healthcareit

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.